62.
Characterization of pancreatic NMDA receptors as possible drug targets for diabetes treatment
by Marquard, Jan
Nature medicine, 2015, Vol.21 (4), p.363-372

63.
The safety evaluation of food flavoring substances: the role of genotoxicity studies
by Gooderham, Nigel J.
Critical reviews in toxicology, 2020, Vol.50 (1), p.1-27

64.
Perceptions of French healthcare students of vaccines and the impact of conducting an intervention in health promotion
by Lepiller, Quentin
Vaccine, 2020, Vol.38 (43), p.6794-6799

65.
Octa-arginine-modified pegylated liposomal doxorubicin: An effective treatment strategy for non-small cell lung cancer
by Biswas, Swati
Cancer letters, 2013, Vol.335 (1), p.191-200

66.
Putative adverse outcome pathways relevant to neurotoxicity
by Bal-Price, Anna
Critical reviews in toxicology, 2015, Vol.45 (1), p.83-91

67.
Molecular docking and ligand specificity in fragment-based inhibitor discovery
by Shoichet, Brian K
Nature chemical biology, 2009, Vol.5 (5), p.358-364

68.
Grey Goo on the Skin? Nanotechnology, Cosmetic and Sunscreen Safety
by Nohynek, Gerhard J
Critical reviews in toxicology, 2007, Vol.37 (3), p.251-277

69.
Cardiovascular Disease Risk Associated With Familial Hypercholesterolemia: A Systematic Review of the Literature
by Wong, Bruce, MBChB, FRACP
Clinical therapeutics, 2016, Vol.38 (7), p.1696-1709

70.
Correlation of structural elements and infectivity of the HET-s prion
by Riek, Roland
Nature, 2005, Vol.435 (7043), p.844-848

71.
Multifaceted role of prohibitin in cell survival and apoptosis
by Peng, Ya-Ting
Apoptosis (London), 2015, Vol.20 (9), p.1135-1149

72.
Is the 3,4-methylendioxypyrovalerone/mephedrone combination responsible for enhanced stimulant effects? A rat study with investigation of the effect/concentration relationships
by Benturquia, Nadia
Psychopharmacology, 2018, Vol.236 (3), p.891-901

73.
Metastatic osteosarcoma challenged by regorafenib
by Heymann, Dominique
The lancet oncology, 2019, Vol.20 (1), p.12-14

74.
Human renal function maturation: a quantitative description using weight and postmenstrual age
by Rhodin, Malin M
Pediatric nephrology (Berlin, West), 2009, Vol.24 (1), p.67-76

75.
Lack of correlation between the activity of the mesolimbic dopaminergic system and the rewarding properties of pregabalin in mouse
by Coutens, Basile
Psychopharmacology, 2019, Vol.236 (7), p.2069-2082

76.
Barriers and motivations for participation in preventive vaccine clinical trials: Experience of 5 clinical research sites
by Detoc, M
Vaccine, 2019, Vol.37 (44), p.6633-6639

77.
Dual contributions of noradrenaline to behavioural flexibility and motivation
by Jahn, Caroline I
Psychopharmacology, 2018, Vol.235 (9), p.2687-2702

78.
Pseudomonas aeruginosa infection in cystic fibrosis lung disease and new perspectives of treatment: a review
by Gaspar, M. C
European journal of clinical microbiology & infectious diseases, 2013, Vol.32 (10), p.1231-1252

79.
Preclinical profile of ITI-214, an inhibitor of phosphodiesterase 1, for enhancement of memory performance in rats
by Snyder, Gretchen L
Psychopharmacology, 2016, Vol.233 (17), p.3113-3124

80.
Opportunities in metabolic engineering to facilitate scalable alkaloid production
by Leonard, Effendi
Nature chemical biology, 2009, Vol.5 (5), p.292-300
